# Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

> **NCT02844933** · PHASE2 · TERMINATED · sponsor: **Radius Pharmaceuticals, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02844933
- **Lead sponsor:** Radius Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-09
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Insys Therapeutics filed Chapter 11 and terminated all studies.
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844933, "Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02844933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*